Monthly Treatment Shows Promise for Kidney Transplant Patients | New Hope for Organ Transplant Recipients | Belatacept & Dazodalibep: A Potential Alternative to Daily Immunosuppressants

For patients who have received an organ transplant, long-term daily treatment is essential, but often difficult to tolerate. A small study suggests that a monthly regimen could, in the future, be a simpler and better-tolerated alternative for patients.

A Potential Shift in Post-Transplant Care

A phase II clinical study indicates that a treatment administered once a month may, over time, replace the multiple daily medications currently used by some kidney transplant patients. Researchers suggest this approach could reduce side effects and potentially prolong the survival of the transplanted organ, according to results published on Tuesday in the American Journal of Transplantation.

Current Challenges with Immunosuppressants

Currently, standard immunosuppressant medications are effective in preventing organ rejection, but they can cause diabetes, high blood pressure, and increased cholesterol. Common side effects also include fatigue, muscle weakness, sexual dysfunction, hair loss, and sleep disturbances.

Study Details and Findings

The pilot phase II study included 23 patients with kidney transplants. These patients received monthly infusions of belatacept (Nulojix), a medication already used in transplantation, in combination with dazodalibep, an experimental drug developed by the American pharmaceutical company Amgen, for four months. Currently, dazodalibep is not approved for clinical use.

Did You Know? The study involved a combination of belatacept, an existing transplant medication, and dazodalibep, a drug currently under development by Amgen.

Both medications work by blocking the immune response directed against the transplanted organ, without affecting other types of cells in the body that are not part of the immune system, unlike standard treatments. In the first 28 days post-transplant, patients also received standard immunosuppressant medications.

Two of the initial patients in the study experienced temporary episodes of organ rejection, leading to adjustments in the frequency and dosage of the medications. Following these changes, 13 patients completed the study protocol. Seven patients withdrew from the study due to acute kidney rejection, adverse effects, or unspecified reasons.

Expert Insight: The study’s findings suggest a potential pathway to reduce the burden of immunosuppressant medications for transplant recipients, focusing those with higher risk factors on the more intensive regimens.

Researchers emphasize that none of the rejection episodes were antibody-mediated, a more difficult-to-treat form where the immune system produces antibodies directed against the transplanted organ.

What’s Next?

The research team intends to test this therapeutic regimen in a larger study, including a greater number of kidney transplant patients. Dr. Allan Kirk, of Duke University School of Medicine in North Carolina, stated, “We hope that most patients can be spared the toxic effects of immunosuppressors, which would only be used in patients with certain increased risk factors.”

Frequently Asked Questions

What is the goal of this new treatment approach?

The goal is to find a simpler, more tolerable treatment option for kidney transplant patients that could potentially replace multiple daily medications with a monthly regimen.

What were some of the side effects of the current standard treatment?

Standard immunosuppressant medications can cause side effects such as diabetes, high blood pressure, increased cholesterol, fatigue, muscle weakness, sexual dysfunction, hair loss, and sleep disturbances.

Were there any issues during the study?

Two patients initially experienced temporary organ rejection, and seven patients withdrew from the study due to acute kidney rejection, adverse effects, or unspecified reasons.

Could a less frequent treatment schedule improve the quality of life for those living with a kidney transplant?